Short Interest in BioRestorative Therapies, Inc. (NASDAQ:BRTX) Decreases By 18.6%

BioRestorative Therapies, Inc. (NASDAQ:BRTX) saw a significant decrease in short interest in the month of March. As of March 31st, there was short interest totalling 329,700 shares, a decrease of 18.6% from the March 15th total of 405,200 shares. Based on an average daily trading volume, of 371,600 shares, the short-interest ratio is presently 0.9 days. Approximately 6.1% of the company’s stock are short sold.

BioRestorative Therapies Stock Performance

Shares of BRTX stock traded down $0.02 during trading hours on Tuesday, hitting $1.70. 6,835 shares of the company were exchanged, compared to its average volume of 616,413. The stock has a market capitalization of $12.72 million, a price-to-earnings ratio of -1.11 and a beta of 68.90. BioRestorative Therapies has a one year low of $1.03 and a one year high of $2.55. The business’s 50-day simple moving average is $1.77 and its two-hundred day simple moving average is $1.73.

BioRestorative Therapies (NASDAQ:BRTX) last announced its earnings results on Thursday, March 27th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.07. BioRestorative Therapies had a negative return on equity of 98.49% and a negative net margin of 2,697.08%. The company had revenue of $0.50 million for the quarter, compared to analyst estimates of $0.48 million. As a group, analysts anticipate that BioRestorative Therapies will post -1.43 EPS for the current fiscal year.

Institutional Trading of BioRestorative Therapies

A hedge fund recently bought a new stake in BioRestorative Therapies stock. Citadel Advisors LLC bought a new stake in BioRestorative Therapies, Inc. (NASDAQ:BRTX) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 21,481 shares of the company’s stock, valued at approximately $31,000. Citadel Advisors LLC owned about 0.31% of BioRestorative Therapies as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 69.38% of the company’s stock.

About BioRestorative Therapies

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.